Statin label to carry diabetes warning
|
All statin labels will now include a warning about a small increased risk for elevated blood glucose levels and possible problems with transient memory and cognition, the FDA announced today.
The agency will also remove existing recommendations to perform routine liver function tests on all patients taking the cholesterol-lowering medications, after concluding, “serious liver injury with statin use is rare and unpredicatable.”
“We want health care professionals and patients to have the most current information on the risks of statins, but also to assure them that these medications continue to provide an important health benefit of lowering cholesterol,” Mary Parks, MD, of the FDA’s Center for Drug Evaluation and Research, said in a press release.